Revlimid Recent News
Biotech Winners And Losers From ASH Conference
Amgen's Kyprolis Fails To Met Endpoint, But It's Not All Bad News
Celgene Reports Second-Quarter Results, Highlights 'Outstanding' 2016 Performance
Celgene To See Major Upside In 2017, Says Canaccord
Celgene Will 'Vigorously' Defend IP Amid Report Kyle Bass Patent Challenge Could Prove Successful
Celgene's EPS Contain 'Few Surprises,' Baird Says